Suppr超能文献

慢性丙型肝炎的治疗:疗效、副作用及并发症

Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.

作者信息

Sandmann Lisa, Schulte Benjamin, Manns Michael P, Maasoumy Benjamin

机构信息

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

出版信息

Visc Med. 2019 Jun;35(3):161-170. doi: 10.1159/000500963. Epub 2019 May 21.

Abstract

BACKGROUND

Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its complications. Viral eradication is essential to prevent disease progression and reduces liver-related mortality and morbidity. Since the availability of direct-acting antivirals (DAA), HCV treatment has changed significantly. Current treatment strategies for different groups of patients as well as potential risks and caveats will be discussed in this review.

SUMMARY

Interferon-free (IFN-free) treatment not only shortens treatment duration, but also achieves high rates of viral clearance and is overall well tolerated. Genotype-restricted but also pangenotypic combinations are available. Usually two DAA of different drug classes are combined. For the majority of the patients, treatment duration ranges from 8 to 12 weeks. Liver and kidney function as well as prior treatment experience and potential drug-drug interactions influence substance choices and treatment duration. However, modern IFN-free treatment is not only safer, but also overall far more simplified and effective. Global HCV eradication might be an ambitious but not completely unrealistic goal to pursue.

KEY MESSAGES

IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life.

摘要

背景

慢性丙型肝炎病毒(HCV)感染可导致肝硬化及其并发症。病毒清除对于预防疾病进展以及降低肝脏相关的死亡率和发病率至关重要。自从直接抗病毒药物(DAA)问世以来,HCV治疗发生了显著变化。本综述将讨论针对不同患者群体的当前治疗策略以及潜在风险和注意事项。

总结

无干扰素(IFN-free)治疗不仅缩短了治疗疗程,还实现了高病毒清除率,并且总体耐受性良好。有基因型限制的以及泛基因型的联合方案可供选择。通常将两种不同药物类别的DAA联合使用。对于大多数患者,治疗疗程为8至12周。肝脏和肾脏功能以及既往治疗经验和潜在的药物相互作用会影响药物选择和治疗疗程。然而,现代的无干扰素治疗不仅更安全,而且总体上更加简化且有效。全球消除HCV可能是一个雄心勃勃但并非完全不切实际的目标。

关键信息

无干扰素抗病毒治疗安全且耐受性良好。患者几乎可以独立于肝功能或伴随疾病进行治疗。病毒清除与发病率和死亡率降低以及生活质量改善相关。

相似文献

8
Treatment of chronic HCV genotype 1 coinfection.慢性丙型肝炎病毒1型合并感染的治疗。
Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4.
10
Direct-acting antivirals: the endgame for hepatitis C?直接作用抗病毒药物:丙型肝炎的终局?
Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15.

引用本文的文献

5
Role of viral hepatitis in pregnancy and its triggering mechanism.病毒性肝炎在妊娠中的作用及其触发机制。
J Transl Int Med. 2024 Oct 1;12(4):344-354. doi: 10.2478/jtim-2024-0015. eCollection 2024 Sep.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验